Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran (Q50751771)

18 March 2018

title

Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran (English)

1 reference

18 March 2018

0 references

1 reference

Hossein Kalanie

1

1 reference

18 March 2018

Kurosh Gharagozli

2

1 reference

18 March 2018

Abolfazl Hemmatie

3

1 reference

18 March 2018

Mehdie Ghorbanie

4

1 reference

18 March 2018

Amir Reza Kalanie

5

1 reference

18 March 2018

publication date

10 November 2004

1 reference

18 March 2018

published in

European Neurology

1 reference

18 March 2018

volume

52

1 reference

18 March 2018

issue

4

1 reference

18 March 2018

page(s)

202-206

1 reference

18 March 2018

Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group.

cites work

1 reference

Immune-mediated demyelination

21 January 2018

1 reference

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

Multiple sclerosis: report on 200 cases from Iran

21 January 2018

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

21 January 2018

1 reference

The role of intravenous immunoglobulin in the treatment of multiple sclerosis

21 January 2018

1 reference

Assessment of MRI criteria for a diagnosis of MS.

21 January 2018

1 reference

Combined immunoglobulin and azathioprine in multiple sclerosis

21 January 2018

1 reference

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study

21 January 2018

1 reference

Beta-interferon and multiple sclerosis

21 January 2018

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

Interferons in relapsing remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

High-dose intravenous immunoglobulin treatment of multiple sclerosis

21 January 2018

1 reference

Central nervous system demyelination and remyelination in multiple sclerosis and viral models of disease

21 January 2018

1 reference

Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis

21 January 2018

1 reference

IV immunoglobulin does not reverse established weakness in MS.

21 January 2018

1 reference

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

Multiple sclerosis: current pathophysiological concepts

21 January 2018

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000082036

1 reference

18 March 2018

1 reference

18 March 2018